Antineutrophil cytoplasmic antibodies (ANCA) are well known to be associated with small vessel vasculitic diseases such as microscopic polyangiitis (MPA), allergic granulomatous angiitis (AGA), and Granulomatosis with poly angiitis: GPA (Wegener's). Disease assessment by 1) vasculitic activity, 2) damage resulting from vasculitis, and 3) patient function, were the required endpoints for the therapeutic trials in ANCA-associated vasculitis (AAV). Harmonized steroids and cyclophosphamide or azathioprine are effective for active AAV. In evaluating tools for monitoring disease, titers of ANCA and the levels of CRP were found useful in AAV. However, it will be important for clinicians to observe AAV patients more closely and reduce immunosuppressive drug doses more cautiously, especially to prevent several infections (i.e., deep mycosis, pneumocystis jirovecii pneumonia and cytomegalovirus). We indicated that strategy of infection control in immunosuppressive therapy for AAV. (J Jpn Coll Angiol, 2009, 49: 93-99).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634993PMC
http://dx.doi.org/10.3400/avd.ra.12.00092DOI Listing

Publication Analysis

Top Keywords

strategy infection
8
infection control
8
control immunosuppressive
8
immunosuppressive therapy
8
anca-associated vasculitis
8
aav
5
therapy anca-associated
4
vasculitis antineutrophil
4
antineutrophil cytoplasmic
4
cytoplasmic antibodies
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!